SOPHiA GENETICS, Inc

Angio-Proteomie is a Boston-based company specializing in the production and distribution of a wide range of high-quality antibodies, primary cells, recombinant proteins, and custom-based services for research and therapeutic purposes. With a diverse catalog of products, including anti-human and anti-mouse antibodies, functional antibodies, signal transduction antibodies, and more, Angio-Proteomie is committed to providing researchers and scientists with the tools they need to advance their studies in various fields, such as angiogenesis, immunology, and cell biology.Generated from the website

CENTOGENE is a leading life science company specializing in rare and neurodegenerative diseases, providing data-driven solutions to patients, physicians, and pharmaceutical companies. With a vast biodatabank of 800,000 individuals and 400,000 collected biosamples, they work collaboratively with patients, physicians, and partners to diagnose, understand, and treat these complex diseases. By integrating omic data and creating comprehensive atlases of rare diseases, CENTOGENE aims to diagnose patients accurately. They also focus on understanding disease pathways and faulty genes to provide valuable insights for pharmaceutical partners in developing targeted treatments. With their multiomic technologies, they identify drug targets with greater certainty, making drug development for rare diseases more financially viable. Their ultimate goal is to enable the cure of 100 diseases within a decade.Generated from the website

AVI BioPharma is a biopharmaceutical company that develops drugs to treat life-threatening diseases using its patented third generation antisense technology. It has completed clinical trials with its NeuGene antisense drugs in more than 300 subjects, addressing cardiovascular restenosis, infectious diseases, cancer, polycystic kidney disease and drug metabolism. Its most advanced cardiovascular program is for restenosis, where it has completed Phase II trials, evaluating its drug, Resten-NG. AVI BioPharma is also in a Phase II clinical trial with a drug for Hepatitis C infection and its influenza A drug candidate has been confirmed to have efficacy against avian influenza H5N1 in preclinical studies. AVI BioPharma maintains a location in Portland, Ore.